Volume 124, Issue 4 p. 587-599
Epidemiology

The global prevalence of erectile dysfunction: a review

Anna Kessler

Corresponding Author

Anna Kessler

School of Cancer and Pharmaceutical Sciences, King's College London, Translational Oncology and Urology Research (TOUR), London, UK

Correspondence: Anna Kessler, Research Oncology, Faculty of Life Sciences and Medicine, School of Cancer and Pharmaceutical Sciences, King's College London, Translational Oncology and Urology Research (TOUR), 3rd Floor, Bermondsey Wing, Guy's Hospital, London SE1 9RT, UK.

e-mail: [email protected]

Search for more papers by this author
Sam Sollie

Sam Sollie

School of Cancer and Pharmaceutical Sciences, King's College London, Translational Oncology and Urology Research (TOUR), London, UK

Search for more papers by this author
Ben Challacombe

Ben Challacombe

Urology Centre, Guy's and St Thomas’ NHS Foundation Trust, London, UK

Search for more papers by this author
Karen Briggs

Karen Briggs

Urology Centre, Guy's and St Thomas’ NHS Foundation Trust, London, UK

Search for more papers by this author
Mieke Van Hemelrijck

Mieke Van Hemelrijck

School of Cancer and Pharmaceutical Sciences, King's College London, Translational Oncology and Urology Research (TOUR), London, UK

Search for more papers by this author
First published: 02 July 2019
Citations: 179

Abstract

Objective

To evaluate the global prevalence of erectile dysfunction (ED); as well as its association with physiological and pathological ageing by examining the relationship between ED and cardiovascular disease (CVD), benign prostatic hyperplasia (BPH), and dementia. We also aimed to characterise discrepancies caused by the use of different ED screening tools.

Methods

The Excerpta Medica dataBASE (EMBASE) and Medical Literature Analysis and Retrieval System Online (MEDLINE) were searched to find population-based studies investigating the prevalence of ED and the association between ED and CVD, BPH, and dementia in the general population.

Results

The global prevalence of ED was 3–76.5%. ED was associated with increasing age. Use of the International Index of Erectile Function (IIEF) and Massachusetts Male Aging Study (MMAS)-derived questionnaire identified a high prevalence of ED in young men. ED was positively associated with CVD. Men with ED have an increased risk of all-cause mortality odds ratio (OR) 1.26 (95% confidence interval [CI] 1.01–1.57), as well as CVD mortality OR 1.43 (95% CI 1.00–2.05). Men with ED are 1.33–6.24-times more likely to have BPH then men without ED, and 1.68-times more likely to develop dementia than men without ED.

Conclusion

ED screening tools in population-based studies are a major source of discrepancy. Non-validated questionnaires may be less sensitive than the IIEF and MMAS-derived questionnaire. ED constitutes a large burden on society given its high prevalence and impact on quality of life, and is also a risk factor for CVD, dementia, and all-cause mortality.

Conflict of Interest

None declared.